From: A dramatic, objective antiandrogen withdrawal response: case report and review of the literature
Author | Antiandrogen agent(s) | No. of Patients | No. of patients with 50% PSA decline | Duration of Anti-androgen therapy (Months) | Duration of AAWR (Months) |
---|---|---|---|---|---|
Kelly[5] | Flutamide | 3 | 2 | 5–17 | 2–5 |
Collinson[17] | Flutamide | 1 | 1 | 12 | 12 |
Scher[6] | Flutamide | 36 | 10 | NS | 5* |
Scher[15] | Flutamide | 57 | 16 | 16 | 5.6 |
Dupont[7] | Flutamide†| 40 | 32 | 5–7 | 14.5 |
Figg[16] | Flutamide | 21 | 7 | 28 | 3.7 |
Sartor[18] | Flutamide†| 29 | 14 | Median: 27* | 8 |
Herrade[8] | Flutamide | 39 | 11 | Median: 19* | 3.3 |
Small[9] | Flutamide | 82 | 12 | Median: 21.5* | 3.5 |
Small[10] | Bicalutamide | 1 | 1 | 32 | 2 |
Nieh[19] | Bicalutamide | 3 | 2 | 24–35 | 2–4 |
Schellhammer [11] | Flutamide/Bicalutamide‡ | 22 | 8 | 16 months combined with LHRH agonist | NS |
Small[14] | Flutamide/Bicalutamide/Nilutamide | 132 | 15 | NS | 5.9 |
Gomella[12] | Nilutamide | 1 | 1 | 11 | 3 |
Huan[13] | Nilutamide††| 2 | 2 | 10 and 15 | 7 and 6 |